BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced results from the Phase 1 clinical study of PEG-PAL for the treatment of phenylketonuria ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE